Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00005270
Other study ID # 1154
Secondary ID U01HL054498
Status Completed
Phase N/A
First received May 25, 2000
Last updated September 1, 2016
Start date September 1995
Est. completion date August 2008

Study information

Verified date August 2008
Source National Heart, Lung, and Blood Institute (NHLBI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

To map the major genetic loci underlying hypertension in approximately 1700 sibling pairs of Asian-Pacific Chinese and Japanese origin. The study consists of a two grant network, which in turn is part of an NHLBI initiative, the Family Blood Pressure Program (FBPP) consisting of four networks.


Description:

BACKGROUND:

Hypertension, a complex disease involving the interplay of genetic and environmental factors, affects an estimated 50 million Americans and is a major predisposing factor for myocardial infarction, vascular disease, stroke, and renal failure. It has been estimated from segregation analysis and twin studies that approximately 45 percent of the interindividual differences in blood pressure are accounted for by genetic differences. The identification of the genes whose variants contribute to high blood pressure will have far-reaching effects on our understanding of the pathophysiology of the circulation and may suggest new preventive measures and rational therapeutic approaches.

One of the principal advantages of the genetic approach is that it identifies primary molecular defects. As a result, it will be possible to stratify the general hypertensive population into subgroups based on genotype and intermediate phenotype and thereby evaluate preventive strategies and therapeutic approaches in more homogeneous groups. In addition, the identification of hypertensive genes also provides the basis for an understanding of the interactions between genes and environmental factors. It is very likely that particular environmental variables exert their effects only in the presence of certain genotypes.

Until recently, the techniques for dissecting the genetic determinants of high blood pressure were not available or were not developed to an extent that would make the Family Blood Pressure Program initiative feasible. However, several recent advances in technology and analytical methods, together with the rapid construction of genetic maps, have substantially improved the chances of detecting these genetic factors.

The concept for the Family Blood Pressure Program was conceived in the Report of the Expert Panel on Genetic Strategies for Heart, Lung, and Blood Diseases. The initiative was approved by the Arteriosclerosis, Hypertension, and Lipid Metabolism Advisory Committee (AHLMAC) in March, 1993. The genetic-epidemiological aspects were approved by the Clinical Applications and Prevention Advisory Committee (CAPAC) in February, 1993. The Request for Applications was released in March, 1994. Awards were made in September, 1995.

DESIGN NARRATIVE:

The study focused attention on an Asian population in order to reduce heterogeneity of the genetic background. In 1995, a genetic network was established in the San Francisco Bay Area, Hawaii, and Taiwan, recruiting an estimated 1,700 affected hypertensive sibpairs plus several multigenerational hypertensive pedigrees of Asian Pacific Chinese and Japanese. Linkage analysis was used to map and identify the genes for hypertension in this ethnic group. A new genetic map of the human genome with 2041 ordered polymorphic markers with an average interval of less than 3 cM had been reported. Such a dense map of polymorphic markers made it plausible to propose linkage analysis of complex traits. A total genomic search was performed on 1700 affected sibpairs and family members. In addition, the candidate gene approach was also used. To address the possibility of heterogeneity of the hypertensive trait, a number of intermediate phenotypes was studied that may help identify more homogeneous subgroups of hypertension. For example, Asians and Pacific Islanders had an increased risk for hypertension, dyslipidemia, and glucose intolerance (Syndrome X) that were associated with hyperinsulinemia. Therefore, hypertension was investigated according to insulin sensitivity vs. resistance as well as other intermediate phenotypes related to hypertension pathophysiology such as renin, Ang II, and endothelin. The hypothesis was that by focusing on possible hypertensive subsets with well defined phenotypes, the possibility was enhanced of gene identification for hypertension in these patients. The third approach examined the hypothesis that there existed a dominant locus determining hypertension in a subset of affected individuals using the analysis of multigenerational pedigrees with 10-13 meiosis separating affected members. If such a subset existed, this approach would reduce the likelihood of heterogeneity and increase the probability of revealing genetic linkage. Once major gene loci were identified, it was important to determine the prevalence of these loci in the overall population and the risk associated with their loci for the development of hypertension. Therefore, the genetic epidemiology of the loci were studied using epidemiological methodologies such as association studies and case control analysis on well characterized populations in Hawaii and Taiwan that had been studied prospectively for many years.

The Family Blood Pressure Program, including the SAPPHIRe Network, was renewed in FY 2000. The Family Blood Pressure Program as a whole carried out five specific aims in the renewal period. These aims were grouped according to two complementary themes: First, the investigators created and analyzed a database of blood pressure-related phenotype and genotype data from all FBPP participants (Aim 1). Within linked regions, they identified allelic variation within positional candidate genes and evaluated the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they used quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network, including SAPPHIRe, carried out its own specific aims alone, based on unique aspects of their population and interests and expertise of the investigators.

SAPPHIRe investigators refined the hypertensive phenotype in the study population by assessing the intermediate phenotype of insulin resistance using the oral glucose tolerance test and steady state plasma glucose assay. They also used novel molecular genetic approaches to enrich genomic DNA for common genetic variations and develop proteomic approaches to identify proteins that were differentially expressed in plasma and urine of the SAPPHIRe participants.

In the next phase of the FBPP which extends through August, 2008, a major emphasis is placed on making the Program a shared resource for hypertension researchers in the United States and throughout the world. In Aim 1, the investigators will build, maintain and update a publicly available knowledge-base to facilitate research by non-FBPP investigators on the genetics of hypertension, its risk factors and its complications. In Aim 2, they will use state-of-the-art genetic linkage analysis methods to identify additional linkage regions using subgroups of pedigrees and physiologically relevant combinations of phenotypes that will aid in localizing hypertension genes. In Aim 3, they will use a combination of bioinformatics, a dense array of SNPs, and state-of-the-art data analysis to follow-up regions of interest and identify the underlying hypertension genes. The regions to be followed-up include those identified during the current phase of the FBPP and Aim 2 of this renewal phase. In Aim 4, they will evaluate the hypertension genes identified in Aim 3 for their association with multiple measures reflecting the cardiovascular and renal complications of hypertension, including left ventricular mass and microalbuminuria. It is the long-term goal of the FBPP to have the hypertension genetics community develop a comprehensive picture of the genetic architecture of human hypertension, including its risk factors, complications, and response to treatment.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date August 2008
Est. primary completion date August 2008
Accepts healthy volunteers No
Gender Both
Age group N/A to 100 Years
Eligibility No eligibility criteria

Study Design

N/A


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Kuakini Medical Center National Heart, Lung, and Blood Institute (NHLBI)

References & Publications (19)

An P, Freedman BI, Hanis CL, Chen YD, Weder AB, Schork NJ, Boerwinkle E, Province MA, Hsiung CA, Wu X, Quertermous T, Rao DC. Genome-wide linkage scans for fasting glucose, insulin, and insulin resistance in the National Heart, Lung, and Blood Institute Family Blood Pressure Program: evidence of linkages to chromosome 7q36 and 19q13 from meta-analysis. Diabetes. 2005 Mar;54(3):909-14. — View Citation

Bielinski SJ, Lynch AI, Miller MB, Weder A, Cooper R, Oberman A, Chen YD, Turner ST, Fornage M, Province M, Arnett DK. Genome-wide linkage analysis for loci affecting pulse pressure: the Family Blood Pressure Program. Hypertension. 2005 Dec;46(6):1286-93. Epub 2005 Nov 14. — View Citation

Chuang LM, Hsiung CA, Chen YD, Ho LT, Sheu WH, Pei D, Nakatsuka CH, Cox D, Pratt RE, Lei HH, Tai TY. Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance. J Mol Med (Berl). 2001 Nov;79(11):656-64. — View Citation

Jorgenson E, Tang H, Gadde M, Province M, Leppert M, Kardia S, Schork N, Cooper R, Rao DC, Boerwinkle E, Risch N. Ethnicity and human genetic linkage maps. Am J Hum Genet. 2005 Feb;76(2):276-90. Epub 2004 Dec 30. — View Citation

Kraja AT, Rao DC, Weder AB, Cooper R, Curb JD, Hanis CL, Turner ST, de Andrade M, Hsiung CA, Quertermous T, Zhu X, Province MA. Two major QTLs and several others relate to factors of metabolic syndrome in the family blood pressure program. Hypertension. 2005 Oct;46(4):751-7. Epub 2005 Sep 19. — View Citation

Kraja AT, Rao DC, Weder AB, Mosley TH, Turner ST, Hsiung CA, Quertermous T, Cooper R, Curb JD, Province MA. An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. Nutr Metab (Lond). 2005 Aug 2;2:17. — View Citation

McAllister L, Penland L, Brown PO. Enrichment for loci identical-by-descent between pairs of mouse or human genomes by genomic mismatch scanning. Genomics. 1998 Jan 1;47(1):7-11. — View Citation

Morrison AC, Cooper R, Hunt S, Lewis CE, Luke A, Mosley TH, Boerwinkle E. Genome scan for hypertension in nonobese African Americans: the National Heart, Lung, and Blood Institute Family Blood Pressure Program. Am J Hypertens. 2004 Sep;17(9):834-8. — View Citation

Province MA, Boerwinkle E, Chakravarti A, Cooper R, Fornage M, Leppert M, Risch N, Ranade K. Lack of association of the angiotensinogen-6 polymorphism with blood pressure levels in the comprehensive NHLBI Family Blood Pressure Program. National Heart, Lung and Blood Institute. J Hypertens. 2000 Jul;18(7):867-76. — View Citation

Province MA, Kardia SL, Ranade K, Rao DC, Thiel BA, Cooper RS, Risch N, Turner ST, Cox DR, Hunt SC, Weder AB, Boerwinkle E; National Heart, Lung and Blood Institute Family Blood Pressure Program. A meta-analysis of genome-wide linkage scans for hypertension: the National Heart, Lung and Blood Institute Family Blood Pressure Program. Am J Hypertens. 2003 Feb;16(2):144-7. — View Citation

Ranade K, Hinds D, Hsiung CA, Chuang LM, Chang MS, Chen YT, Pesich R, Hebert J, Chen YD, Dzau V, Olshen R, Curb D, Botstein D, Cox DR, Risch N. A genome scan for hypertension susceptibility loci in populations of Chinese and Japanese origins. Am J Hypertens. 2003 Feb;16(2):158-62. — View Citation

Ranade K, Hsuing AC, Wu KD, Chang MS, Chen YT, Hebert J, Chen YI, Olshen R, Curb D, Dzau V, Botstein D, Cox D, Risch N. Lack of evidence for an association between alpha-adducin and blood pressure regulation in Asian populations. Am J Hypertens. 2000 Jun;13(6 Pt 1):704-9. — View Citation

Ranade K, Shue WH, Hung YJ, Hsuing CA, Chiang FT, Pesich R, Hebert J, Olivier M, Chen YD, Pratt R, Olshen R, Curb D, Botstein D, Risch N, Cox DR. The glycine allele of a glycine/arginine polymorphism in the beta2-adrenergic receptor gene is associated with essential hypertension in a population of Chinese origin. Am J Hypertens. 2001 Dec;14(12):1196-200. — View Citation

Ranade K, Wu KD, Hwu CM, Ting CT, Pei D, Pesich R, Hebert J, Chen YD, Pratt R, Olshen R, Masaki K, Risch N, Cox DR, Botstein D. Genetic variation in the human urea transporter-2 is associated with variation in blood pressure. Hum Mol Genet. 2001 Sep 15;10(19):2157-64. — View Citation

Ranade K, Wu KD, Risch N, Olivier M, Pei D, Hsiao CF, Chuang LM, Ho LT, Jorgenson E, Pesich R, Chen YD, Dzau V, Lin A, Olshen RA, Curb D, Cox DR, Botstein D. Genetic variation in aldosterone synthase predicts plasma glucose levels. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13219-24. Epub 2001 Oct 30. — View Citation

Tang H, Quertermous T, Rodriguez B, Kardia SL, Zhu X, Brown A, Pankow JS, Province MA, Hunt SC, Boerwinkle E, Schork NJ, Risch NJ. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005 Feb;76(2):268-75. Epub 2004 Dec 29. — View Citation

Wu KD, Hsiao CF, Ho LT, Sheu WH, Pei D, Chuang LM, Curb D, Chen YD, Tsai HJ, Dzau VJ, Cox D, Tai TY. Clustering and heritability of insulin resistance in Chinese and Japanese hypertensive families: a Stanford-Asian Pacific Program in Hypertension and Insulin Resistance sibling study. Hypertens Res. 2002 Jul;25(4):529-36. — View Citation

Wu X, Cooper RS, Borecki I, Hanis C, Bray M, Lewis CE, Zhu X, Kan D, Luke A, Curb D. A combined analysis of genomewide linkage scans for body mass index from the National Heart, Lung, and Blood Institute Family Blood Pressure Program. Am J Hum Genet. 2002 May;70(5):1247-56. Epub 2002 Mar 28. — View Citation

Zhu X, Luke A, Cooper RS, Quertermous T, Hanis C, Mosley T, Gu CC, Tang H, Rao DC, Risch N, Weder A. Admixture mapping for hypertension loci with genome-scan markers. Nat Genet. 2005 Feb;37(2):177-81. Epub 2005 Jan 23. — View Citation

* Note: There are 19 references in allClick here to view all references

See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A